Lifecore seeks US approval for anti-adhesion gel:
This article was originally published in Clinica
Lifecore Biomedical has filed a premarket approval application with the FDA for its Intergel solution for preventing post-operative adhesions. The fifth and final module of the application, submitted earlier this month, contains an analysis of data from a clinical trial of the ferric hyaluronate product involving over 265 women who underwent intraperitoneal laparotomy procedures, said the Chaska, Minnesota-based company. The product is currently marketed in Europe by the Gynecare Division of Ethicon, a Johnson & Johnson company.
You may also be interested in...
Companion diagnostics are needed increasingly by pharma companies to justify the safety and effectiveness of their products. With specific first-time EU regulation of these products within sight – and urgently needed – is there a risk of delays to these products being able to demonstrate compliance?
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.